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INTRODUCTION 
 
 Tumors of Central Nervous System pose a major diagnostic dilemma due 
to varied presentations and innumerable morphological entities. Among them, 
Gliomas form a major portion of all brain tumors. Glial cells form the support 
system of the Central Nervous System, and are composed of four main cell types: 
Astrocytes, Oligodendrocytes, Microglia and Ependymal cells. The neoplasms in 
the brain are hence named according to the cell of origin. 
 
 Gliomas are the most common brain tumor in adults, accounting for about 
70% of primary neoplasms of the central nervous system (CNS). Glioblastoma, is 
the most common glioma, accounting for approximately 70% of astrocytomas and 
15% of all intracranial neoplasms1. 
 
 WHO grades Gliomas from Grade I to Grade IV, with Glioblastoma being 
graded as Grade IV. Along with the highest-grade Glioblastoma is also associated 
with a fatal outcome as Grade IV tumors are associated with a shorter survival 
period. Histopathologically, high grade gliomas are seen to frequently exhibit 
necrosis, vascular proliferation and increased mitotic activity2. 
 
 The most frequent genetic alteration associated with Glioblastoma is 
amplification of the epidermal growth factor receptor (EGFR) gene, which results 
in over expression of EGFR, a transmembrane tyrosine kinase receptor. High 
protein levels of EGFR occur in about 90% of astrocytic tumors, suggesting that 
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alterations in transcription and translation of this gene may also participate in 
tumorigenesis1,2.  
 
 Amplifications and rearrangements of EGFR are highly indicative of high-
grade gliomas.  
 
High grade gliomas are also associated with increased mitotic activity due to high 
cell turnover, which can be assessed by Ki 67 Labelling Index. Expression of 
EGFR and Ki-67 has been seen to significantly correlate with the histological 
grade of the glioma2.  
 
 Few studies show that EGFR immunopositivity was significantly higher in 
grade III and IV gliomas compared with grades I and II. The mean Ki-67 labelling 
index (LI) was also seen to significantly increase in the higher glioma grades2.  
 
 It has also been observed that dysregulation of EGFR enhances tumor 
growth, migration, angiogenesis, and metastatic spread. Additionally, EGFR 
overexpression is a poor prognostic factor and correlates with decreased overall 
survival in Glioblastoma patients3. 
 
 In medicine, the study of EGFR expression has become important due to 
targeted therapy. Role of EGFR inhibitors aiming to promote apoptosis of cancer 
cells and possible adjuvant therapies is being extensively researched. 
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 Considering the evidence from above stated studies, higher grade gliomas 
have poor prognosis and also show EGFR and Ki67 positivity. Their evaluation 
and grading have further implications in management of such cases. Hence to 
elaborate this, we aimed to study the correlation of EGFR and Ki 67 
immunolabelling in conjunction with grading of glioma. 
  
Aims and Objectives 
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AIMS & OBJECTIVES 
 
 The aim of the study was to evaluate the expression of EGFR and Ki-67 
immunolabelling in gliomas. 
 
The objectives of the study were, 
1. To correlate the expression of EGFR and Ki 67 with WHO grading of 
gliomas. 
2. To study the age, sex, site and few histological parameters like necrosis 
and vascular proliferation in different types of gliomas 
3. To evaluate EGFR expression in gliomas as a useful tool for diagnostic and 
therapeutic purposes. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 The Central Nervous System comprises of two principal types of cells, the 
neurons and the supporting cells or neuroglia. Glial cells are of two types 
Macroglia and Microglia.  
 
Neuroglial cells are primarily of four types1,2- 
1. Oligodendrocytes - Responsible for formation of myelin in the central 
nervous system 
 
2. Astrocytes - These are highly branched cells that pack the interstices 
between the neurons, neuronal processes and oligodendrocytes. Their 
function is to provide mechanical support, help in exchange of metabolites 
between the neurons and the vascular system, take part in the formation of 
blood brain barrier, and also play an important role in repair of tissue 
following damage. They are so called because of their star shaped 
appearance, caused by multipolar branching cytoplasmic processes which 
have cytoplasmic intermediate filaments and Glial Fibrillary Acidic 
Protein. 
 
3. Microglia - Represent the Monocyte-Macrophage system. Their function is 
to phagocytose neurons that undergo programmed cell death during 
development. These cells respond to injury by proliferation and by 
producing nodules of microglia. 
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4. Ependymal cells - Cuboidal cells that lines the ventricles and spinal canal. 
 
 Macroglia are composed of astrocytes, oligodendrocytes and ependymal 
cells, and are derived from the neuroectoderm, while Microglial cells are derived 
from the mesoderm1,2. 
 
 CNS neoplasms were first discovered by a Russian Scientist, Gupta 
Longati in the year 1873. Primary CNS neoplasms account for 2% of all cancers, 
and 20% of these cancers occur in children under 15 years of age3. 
 
 Neurogenesis in adults is thought to be responsible for the replacement of 
neurons and glia for the purposes of cellular replenishment, remodeling and 
response to injury 4.  
 
 There are two identified neurogenic niches in the adult mammalian brain: 
the sub ventricular zone (SVZ) and the sub granular zone4,5.  
 
 The sub ventricular zone (SVZ) is an extensive germinal layer adjacent to 
the ependyma that concentrates stem cells on the walls of the lateral ventricles6. 
 
Gliomas are derived from neuronal progenitors or Neuronal Stem Cells 
(NSCs)4. Neural stem cells and their progeny have become candidates for the cell 
of origin of glioma since the discovery of neurogenesis in the adult brain. These 
cancer stem cells provide a reservoir of cells with self-renewal capabilities and 
maintain tumors by generating differentiated tumor cells. They are also regarded 
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to play an essential role in recurrence after chemo-radiotherapy. Therefore, the 
identification of cancer stem cells and understanding the mechanisms by which 
cancer stem cells act appear to be crucial for the development of treatments for 
these intractable tumors, as lately cancer stem cells have been shown to exhibit 
resistance to radiation and chemotherapeutic drugs4,5,6 
 
EPIDEMIOLOGY OF BRAIN TUMORS 
 As of 2015, worldwide, brain tumors are the most common cancer in age 
group 0-19 years and is also estimated to be the leading cause of cancer 
related deaths in children of the same age group. Meningiomas represent 
36.4% of all primary brain tumors, making them the most common primary 
brain tumor7-9. 
 Gliomas, represent 27% of all brain tumors and 80% of all malignant 
tumors. 
 Glioblastomas represent 15.1% of all primary brain tumors, and 55.1% of 
all gliomas7-10. 
 Astrocytomas, represent 75% of all gliomas. 
 Oligodendrogliomas represent nearly 2% of all primary brain tumors7-10. 
 Medulloblastomas/embryonal/primitive tumors represent 1% of all primary 
brain tumors. 
 Pituitary tumors represent 15.5% of all primary brain tumors7-10. 
 
 Highlighting the Indian Scenario, in 2015 the incidence (newly diagnosed 
cases of cancer in a year) of Brain Tumors was about 2 patients per 1,00,000 
 
8 
 
 
population, while the mortality rate (deaths due to brain cancer) was less than 2 
patients per 1,00,000 population. Glioblastoma (GBM) was the most common 
brain and Central Nervous System (CNS) malignancy, accounting for about 
45.2% of malignant primary CNS tumors, 54% of all gliomas and 16% of all 
primary CNS tumors10,11.  
 
 National Cancer Registry Programme (NCRP) of Indian Council of 
Medical Research (ICMR)11, studied the trends in cancers of central nervous 
system in both the sexes, in five population based cancer registries (Mumbai, 
Chennai, Bangalore, Delhi and Bhopal) over a period of two decades from 1982-
2003. Age adjusted incidences were used and it was derived separately for each of 
the five cancer registries. Separate data was arrived at for males and females. The 
starting period was taken as (1982-83) and the end of period (2002-03) in both the 
sexes for the registry11. 
 
 According to the Chennai registry, CNS tumors ranked 9th in males and 
8th in females. The average age adjusted incidence rates for CNS cancers, ranged 
in males from 2.53 to 4.14, while in females it ranged from 1.46 to 2.6611. 
 
 Pediatric brain tumors vary considerably in their histological, 
topographical and gender distribution throughout childhood and adolescence, 
reflecting different dynamics of individual tumor entities 12,13,14.  
 
 Overall the prevalence for boys (60.9%) was higher and supra-tentorial 
locations predominated (53.3%); there was an even distribution of low-grade 
 
9 
 
 
WHO I/II (51.5%) and high-grade WHO III/IV (48.5%) tumors. Boys were more 
commonly affected in all age groups throughout childhood and adolescence. 
Infratentorial location was more common between the ages of 3 and 11 years (57. 
5%).The main histological entities were pilocytic astrocytomas (23.5%), followed 
by medulloblastomas (16.3%), ependymomas (10.1%), anaplastic astrocytomas 
and glioblastomas (7.2% each), and craniopharyngiomas (5.6%); astrocytomas 
overall accounted for 47.3% of pediatric brain tumors13,14. 
 
 In India, a study conducted by Satyanarayana et al revealed that the age 
adjusted incidence rates of pediatric CNS tumors in boys was 6.6-19.8 and in girls 
was 3.0-16.0128. 
 
 In a study conducted by Arora et al, CNS tumors are the second most 
common childhood cancer (22-25%) and lymphomas are the third common 
(10%). In India lymphomas often exceed CNS tumors, particularly in males. Not 
only is the proportion of lymphomas higher in India, Hodgkin’s Lymphoma (HL) 
exceeds Non-Hodgkin's lymphoma (NHL). This specifically seems to be a result 
of the high incidence of HL in male children in India in the larger urban areas of 
Bangalore, Chennai, Delhi, and Mumbai. The incidence rate of CNS tumors is 10-
20 per million children, per year, which is half of that when compared to the 
statistics from all around the world14. 
 
 In a study conducted by Jain et al, the most common primary pediatric 
brain tumors were astrocytic tumors (34.7%), followed by medulloblastoma and 
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supratentorial primitive neuro-ectodermal tumors (22.4%), craniopharyngiomas 
(10.2%) and ependymal tumors (9.8%)15.  
 
 CBTRUS-The Central Brain Tumor Registry of the United States-analyzed 
data from 2009 to 2013, which consisted of new cases and incidence rates of 
malignant and benign primary tumors of CNS, pituitary and olfactory tumors of 
nasal cavity (lymphoma, leukemia)16. Data was obtained from Center for Disease 
Control and prevention & National Program of Cancer Registries. Incidence of all 
primary malignant CNS tumors is 22.36 per 1,00,000 of a total count of 3,68,000 
incident tumors. Rate was found to be higher in females (24.46/1,00,000) than 
males (20.10/1,00,000). In the age group of 0-19 years according to CBTRUS the 
incidence was 5.67/1,00,00016. 
 
The 5-year survival rate according to the age group was as follows, 
 0-19 years-73.8% 
 20-44 years-61.5% 
 45-54 years-33.5% 
 55-64 years-18.55% 
 65-74 years-11.2% 
 >75 years-6.3 % 
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EPIDEMIOLOGY OF GLIOMAS 
 Diffuse astrocytomas- account for 10-15% of all brain tumors. According 
to a study conducted by Dasgupta et al, in India Astrocytomas represent the 
largest and most prevalent tumor of adult brain17-20. 
 Pilocytic Astrocytoma- Pilocytic astrocytoma is the most common primary 
brain tumor of childhood. They constitute 70-85% of all 
cerebellar astrocytomas, 5.2% of all primary central nervous system 
gliomas. Pilocytic astrocytoma constitutes approximately 19% of all 
central nervous system tumors among patients aged 0-14 years and 
approximately 12% among those aged 15-19 years17-20. 
 Oligodendroglioma- Oligodendroglioma is  the least common of all glial 
tumors accounts for 2%–5% of primary brain tumors and 5%–18% of 
all glial neoplasms. Age adjusted incidence rates are 0.32/100000-person 
years. The peak age of incidence is 4th to 5th decade 21. 
 Anaplastic Oligodendroglioma-it is quite rare accounting to <2% of glial 
tumors. It constitutes 1.2% of all primary brain tumors with an age adjusted 
annual incidence of 0.17/100000-person years 22. 
 Ependymoma-In children aged 0-14 years, ependymomas accounted for 
5.7% of all tumors diagnosed. Approximately 185 children are diagnosed 
with ependymoma per year. In children aged 15-19 years, ependymoma 
accounted for 4% of all tumors diagnosed. For tumors involving the spinal 
cord, spinal meninges and cauda equina, ependymomas accounted for 
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20.5% of all tumors diagnosed. In adults 20+ years, ependymomas 
accounted for 1.9% of all tumors diagnosed 23. 
 Anaplastic Ependymoma-the incidence was equal in males and females 
 For those with ependymoma, the overall 5-year relative survival rate is 
83.4%. 5-year relative survival rates are highest for those aged 20-44 years 
(91%), and decrease with increasing age at diagnosis with a 5-year relative 
survival rate of 57.8% for those aged 75+ years. For children aged 0-19, 
the 5-year relative survival rate is 75.2% 23. 
 Subependymomas-10% of ependymomas, most often present as incidental 
autopsy findings in the brains of the elderly 22,23. 
 Myxopapillary ependymomas-arise most frequently in adults; 
approximately 20% occur in children, in whom there is a 2:1 male-to-
female tendency for dissemination through Cerebrospinal Fluid (CSF) 
pathways. Anaplastic ependymomas are far more common in the pediatric 
age group, frequently arising in a supratentorial location 22,23. 
 Sub ependymoma- represents 8% of all ependymal tumors23. 
 Pleomorphic Xantho-astrocytoma- is an uncommon astrocytic neoplasm 
which constitutes <1% of gliomas. So far only 200 cases have been 
reported in literature. This tumor occurs more commonly in young adults, 
between second to third decade 24,25. 
 Glioblastoma (GB) accounts for 15-17% of all primary brain tumors. GB 
accounts for about 50-65% of all astrocytic tumors. GB has an age adjusted 
incidence of 2-3/100,000-person years. For adults with more aggressive 
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glioblastoma, treated with concurrent temozolamide and radiation therapy, 
median survival is about 14.6 months and two-year survival is 30%. 
However, a 2009 study reported that almost 10% of patients with 
glioblastoma may live five years or longer. Supra-tentorial and cerebellar 
tumors are more amenable to surgical treatment and thus carry better 
prognosis than tumors in the brainstem or diencephalon 26,27,28. 
 Gliosarcoma- It is the neoplasm with mixed glial and sarcomatous 
elements. It has an increased rate of metastases and has not been found to 
carry the hallmark of EGFR overexpression generally found in 
glioblastomas 29,30. 
 
SYMPTOMS OF CNS TUMORS 
The location of CNS tumors will determine the symptoms of patients.  
The usual presentations are 
1. Epilepsy (focal or generalized) 
2. Focal neurologic deficits     
3. Symptoms and signs of raised intracranial include-headache (particularly 
postural and nocturnal or early morning), vomiting (particularly children), 
clouding of consciousness and coma, papilledema 31,32,33.      
 
Neoplasms and cysts that often present with hydrocephalus include: 
1. Any posterior fossa neoplasm (particularly medulloblastoma and 
ependymoma). 
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2. Pineal gland neoplasms.  
3. Sub ependymal giant cell astrocytoma.      
4. hypothalamic pilocytic astrocytoma.     
5. central neurocytoma.    
6. chordoid glioma of the third ventricle.     
7. colloid cyst of the third ventricle. 
 
 Lesions such as oligodendroglioma, anaplastic oligodendroglioma and 
gliosarcoma have a predilection for the frontal lobe, hence present with behavioral 
changes 31,32,33. 
 
Neoplasms that present with raised intracranial pressure are- 
1. Ependymoma. 
2. Anaplastic ependymoma. 
3. Oligodendroglioma. 
4. Glioblastoma 31,32,33. 
 
RISK FACTORSAND ETIOLOGICAL FACTORS- 
1. AGE & SEX- 
Studies show that the incidence of glioma increase exponentially after the 
4th decade. Gliomas are more common in males than females in the ratio of 
60:40 34. 
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2. RADIATION- 
Ionizing radiation in the form of x-rays and gamma rays is the only 
exposure which the International Agency for Research on Cancer (IARC) 
classifies as a cause of brain and CNS tumors 34,35. Evidence on the effects 
of ionizing radiation came initially from studies of atomic bomb survivors, 
ionizing radiation overall generally appears to be more strongly associated 
with meningioma risk than with glioma risk. The risk of meningioma is 
increased by 64-100% with each Gray (Gy) of ionizing radiation exposure 
received. Age at exposure, sex, and time since exposure does not appear to 
modify the effect of radiation on meningioma risk. The risk of glioma 
appears to be increased by 8%-56% per Gy. Younger age at exposure 
confers a stronger effect on glioma risk35. 
 
Brain tumor risk is almost tripled in people who received 1-2 CT scans 
(total average X-ray dose around 60 milli-gray (mGy)) during childhood or 
adolescence, large cohort studies have shown 36,37. 
 
Radiotherapy for a primary brain tumor (compared with no radiotherapy) 
was associated with around 55% higher risk of secondary brain tumor, in a 
study of US patients treated between 1973 and 2002 38. 
 
People who received radiotherapy for cancer during childhood have a 14-
fold higher risk of developing glioma later in life, compared with those 
who did not receive radiotherapy for their childhood cancer 39,40. 
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The risk of second primary brain tumor increased linearly with increasing 
radiotherapy dose, with this effect much stronger for meningioma than 
glioma39,40. 
 
NON IONIZNG RADIATION 
 Interphone International Study in 13 countries in 2765 gliomas and 2409 
meningiomas showed no association between mobile phone usage and brain 
tumors 41,42. IARC classifies mobile phone use as a possible cause of glioma and 
acoustic neuroma, based on limited evidence 41,42,43. Most studies have reported no 
significant association between mobile phone use and brain tumor risk at the 
population or individual level 44,45. 
 
GENETIC SYNDROMES AND FAMILY HISTORY- 
 Neurofibromatosis (NF) are a group of genetic conditions. The risk of brain 
and CNS tumors is at least 23-43 times higher in NF1 patients than in the 
general population 46,47. Relative risk of brain tumors in NF1 patients 
increases with patient age 48. Most NF1-associated brain tumors are 
gliomas 48,49. Both children and adults with NF1 have an increased risk of 
astrocytoma, with the tumor grade often higher in adults than children 
49,50. 5-25% of children with NF1 develop optic pathway gliomas 50.  
  Tuberous Sclerosis Complex (TSC) is associated with benign CNS 
tumors. The prevalence of TSC is estimated at around 1 in 25,000 51,52. Up 
to 20% of TSC patients develop sub ependymal giant-cell astrocytomas53. 
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 Li-Fraumeni syndrome is a very rare genetic condition associated with 
increased risk of early-onset brain tumors and other cancer types. 
Astrocytoma’s, glioblastomas, medulloblastomas, and choroid plexus 
carcinomas are the most common brain tumors seen in this population 54-57. 
 Turcot’s syndrome is associated with both brain and bowel tumors. 
Turcot’s syndrome type 1 is associated with early-onset gliomas 58,59,60. 
 
 Having a family history of CNS tumors is associated with increased risk of 
developing brain tumors, those with any first-degree relative diagnosed with 
glioma have a 77% increased risk of developing, and a 2.2- to 2.6-fold risk 
increase if the affected relative is a sibling 61-64. 
 
HORMONAL FACTORS  
 A meta-analysis showed that the Glioma risk is 32% lower in 
postmenopausal hormone replacement therapy (HRT) 65. 
 
OCCUPATIONAL EXPOSURE - 
 Early studies focused on nitroso compounds and polycyclic aromatic 
hydrocarbons because of their abilities to induce brain tumors in animal models, 
but studies have yet to conclusively link brain tumors to exposures to these or 
other neuro-carcinogenic compounds in humans 66-69. 
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 Cadmium is a type I carcinogen associated with human lung, renal, 
bladder, breast, liver, and gastric cancers and ranks first among suspect metals for 
brain tumors. The major sources of personal exposure are occupation, smoking, 
and diet. Studies support the carcinogenic effects of cadmium and show its effects 
on increasing the permeability of the Blood Brain Barrier 70,71,72.  
 
NEUROIMAGING IN GLIOMAS- 
 MRI, CT Scan are the most important investigations in work up of gliomas. 
MRI helps in adjudging the extent of soft tissue involvement. 
 
 Neuroimaging gives valuable information regarding the exact location, 
cerebral edema, fluid collection, extent of involvement, vascularity.  
 
 Other modalities of imaging are PET CT, Magnetic Resonance 
spectrophotometry, Single Photon Emission Computerized Tomography (SPECT) 
70-72 
 
WHO CLASSIFICATION OF CNS TUMORS- 
 For the past century, the classification of brain tumors has been primarily 
dependent on light microscopic features in hematoxylin and eosin-stained 
sections, immune-histochemical expression of lineage associated proteins and 
ultrastructural characterization. The current update (2016 CNS WHO) 
incorporates molecular parameters into the classification of CNS tumor entities 73.  
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The current WHO Classification-2016 has the following advantages: 
 Integrated phenotypic and genotypic parameters for CNS tumor classification 
brings in a level of objectivity. 
 Greater diagnostic accuracy. 
 Improved patient management.  
 Accurate determinations of prognosis and treatment response. 
 
 Histological grading remains the single most important factor in the 
grading of gliomas followed by genotyping of the tumor. 
 
 Whilst reporting of CNS tumors, diagnoses should consist of a 
histopathological name followed by the genetic features - for example, 
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. 
 
 For a tumor lacking a genetic mutation, the term wildtype can be used if an 
official “wildtype” entity exists: Glioblastoma, IDH-wildtype 73. 
 
The revised Grading of Gliomas are- 
GRADE I-Pilocytic Astrocytoma. 
 Sub ependymal Giant Cell Astrocytoma. 
 Myxopapillary Ependymoma. 
 Sub ependymoma. 
 Desmoplastic Infantile Astrocytoma and Ganglioglioma. 
 Angiocentric Glioma. 
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GRADE II-Diffuse Astrocytoma-IDH mutant. 
 Oligodendroglioma-1p/19q co deletion. 
 Pleomorphic Xanthoastrocytoma. 
 Ependymoma. 
 
GRADE III-Anaplastic Astrocytoma-IDH mutant. 
 Anaplastic Oligodendroglioma-IDH mutant and 1p/19q co deletion. 
 Anaplastic Ependymoma. 
 Anaplastic Pleomorphic Xantho-astrocytoma. 
 Anaplastic Oligodendroglioma. 
 
GRADE IV- 
 Glioblastoma  
 Gliosarcoma 
 
PILOCYTIC ASTROCYTOMA 
Pilocytic astrocytoma is classified separately from diffuse astrocytic neoplasms 
because - 
 It does not share their genetic abnormalities     
 Does not infiltrate surrounding tissue in the same manner  
 Very rarely progresses to an anaplastic form   
 Has a predilection for sites not commonly involved by other astrocytic 
neoplasms     
 Has a significantly better prognosis.    
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 It is seen to involve the cerebellum, hypothalamus, optic pathway and third 
ventricle. Children and young adults are commonly affected. The MAPK/ERK 
pathway aberrations, most commonly due to generation of a KIAA1549 - BRAF 
fusion protein with tandem duplication of the BRAF gene. In contrast to diffuse 
astrocytoma’s, PAs lack either IDH1 / 2 or TP53 mutations. Of patients with 
neurofibromatosis type 1, approximately 15% develop a PA. Grossly, it is a 
differential for cyst with a mural nodule. Microscopically, it has a biphasic 
pattern, with microcystic and fascicular pattern. Fascicular pattern is visualized as 
bipolar cytoplasmic processes, these cells have a spindle to oval nucleus with 
fibrillary cytoplasm. Rosenthal fibers and eosinophilic granular bodies are seen 
associated with PA 74-76.  
 
SUBEPENDYMAL GIANT CELL ASTROCYTOMA 
 The most common CNS neoplasm in TSC patients, develops in about 5% 
of TSC patients. Usually occurs in adolescence. Typically situated in the wall of 
the lateral ventricle. It shows autosomal dominant inheritance with high 
penetrance gene on chromosome 9q34 in about half of affected families. A well-
defined soft mass of gray tissue protrudes into the ventricle. Grossly, it is 
predominantly exophytic, and does not invade surrounding parenchyma. 
Calcification may be present. At the microscopic level, many large oval cells have 
abundant glassy eosinophilic cytoplasm and a large eccentric nucleus, but 
elongated cells with smaller nuclei and fibrillary processes may surround groups 
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of the plump cells, forming a nodular pattern. Mitoses are unusual, but their 
presence does not signify aggressive behavior 74,75,76. 
 
OLIGODENDROGLIOMA  
Has a predilection for younger age group. The following mutations are 
responsible, 
 Co deletion of Chromosomes 1p/19q, the presence of which is favorable,  
 MGMT methylation, presence of which is favorable,  
 IDH1 mutation, presence of which is favorable in anaplastic 
oligodendroglioma, 
 CDKN2A deletion, absence of which is favorable,  
 EGFR over expression in anaplastic oligodendroglioma.  
 
 Oligodendrogliomas are composed of uniform cells, these infiltrate gray 
matter. A delicate vasculature consisting of branching capillaries runs through the 
neoplasm. Cytoplasm is sparse. Artefactual clearing of the cytoplasm is common 
in paraffin-embedded material, particularly when fixation is delayed, and gives a 
‘fried-egg’appearance to the cells. Nuclei are round and usually contain faintly 
speckled chromatin. A single small nucleolus may be present 77,78. 
 
ANAPLASTIC OLIGODENDROGLIOMA - 
 It is classified under WHO Grade III. These neoplasms are associated with 
necrosis, increased mitosis, endothelial proliferation and nuclear atypia. There is 
also overexpression of EGFR and increased Ki 67 expression 79,80. 
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EPENDYMOMA - 
 Classic ependymoma presents as an intracranial neoplasm in childhood. 
The myxopapillary ependymoma, which has a more indolent behavior than the 
classic ependymoma, nearly always presents as a spinal neoplasm in adulthood. 
Ependymomas are generally composed of sheets of uniform cells with indistinct 
cytoplasmic borders and round or oval nuclei. Mitoses should be infrequent. The 
pseudo rosette is a perivascular anuclear zone of fibrillary processes that taper 
towards the vessel. Pseudo rosettes are a frequent, not specific, finding in 
ependymomas. Ependymal (true)rosettes with a central lumen and a halo of 
neoplastic cells are more specific, but found less consistently 81,82. 
 
 Cellular ependymomas contain cells with a high nuclear: cytoplasmic ratio. 
Differentiating this variant from an anaplastic ependymoma is difficult, and 
depends on the identification of an increased mitotic count and cytologic 
pleomorphism in the latter. Microvascular proliferation and abundant necrosis are 
also features of most anaplastic ependymomas 82,83,84.  
 
 Clear cell ependymoma-may be confused with an oligodendroglioma, but 
the presence of pseudo rosettes helps in differentiating.  
 
 Criteria for the diagnosis of Anaplastic ependymoma-WHO GRADE III 
are Necrosis and capillary endothelial proliferation. The WHO classification 
emphasizes atypical cytologic features (i.e. nuclear pleomorphism), a high cell 
density, and plentiful mitoses in its diagnosis. 
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 It is important to note that no histologic feature of ependymomas correlates 
reliably with prognosis 82-84. 
 
MYXOPAPILLARY EPENDYMOMA - 
Myxopapillary ependymoma is a slow-growing tumor, arising 
predominantly in the region of the filum terminale It has also been described in 
extra-spinal locations including extradural/subcutaneous tissue, cervical thoracic 
spine, lateral ventricle, and the brain. There is a slight male predominance. 
Grossly, they are well defined, sausage shaped tumors with a smooth surface. 
Histologic sections reveal numerous small papillary structures surrounded by 
single layer of cuboidal or columnar cells. The cells have round nuclei and 
delicate chromatin and lack obvious cytoplasmic processes. The cores of the 
papillae are either completely filled up with the mucinous/myxoid matrix or have 
a central blood vessel surrounded by the matrix. Other areas can show a loose 
structure with microcystic spaces formation or more compact gliofibrillar areas 
resembling typical ependymomas with perivascular pseudo rosettes or even true 
ependymal rosettes. Mitotic figures are not usually seen. Clusters of bland nuclei 
embedded in a dense, fine, glial fibrillary background. Mild nuclear 
pleomorphism, microcystic formations (only in lateral ventricular tumors. 
occasional ependymal pseudo rosettes, hemorrhage, calcification may be seen. 
Mitoses is very rare 85,86. 
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Sub ependymomas- are composed of cells with uniform, round or oval nuclei 
and generally scanty perinuclear cytoplasm. The cells are clustered in small, 
scattered groups and separated by broad bands of closely packed fibrillary 
processes. Occasional cells have more abundant, homogeneous, perinuclear 
cytoplasm. Mitoses are absent 86. 
DIFFUSE ASTROCYTOMA - 
 Astrocytoma, anaplastic astrocytoma, and glioblastoma constitute a range 
of diffusely infiltrating astrocytic neoplasms, which occur throughout the CNS. 
They are referred to as ‘diffuse astrocytic tumors’ to distinguish them from the 
pilocytic astrocytoma and other rarer forms of localized or circumscribed 
astrocytic neoplasms (e.g. pleomorphic xantho-astrocytoma and sub ependymal 
giant cell astrocytoma). The diffuse astrocytic neoplasms are commonest in the 
cerebrum in adults and brain stem in children 87-89. 
 
GENETICS OF DIFFUSE ASTROCYTOMA 
 The origin of astrocytic neoplasms may include neural stem cells, 
progenitor cells, or differentiated glial cells. Isocitrate dehydrogenase (IDH1, 
IDH2) and TP53 gene mutations are considered to be early events in neoplastic 
progression. PDGFRA overexpression is seen in about 60% of cases. Promoter 
hypermethylation of p14ARF gene occurs in 30% of cases. There is loss of 
chromosome 19q accounts to progression to anaplastic astrocytoma. IDH1 
mutation is associated with better prognosis. IDH1/2 mutation is common in 
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astrocytoma, oligodendroglioma, oligoastrocytoma, and their anaplastic 
counterparts 87-89,90,91. 
 
 Macroscopically, Cerebral astrocytoma’s diffusely expand the white 
matter, sometimes distorting the overlying gray matter. The neoplastic process is 
poorly demarcated. Macroscopic cyst formation can occur. Cysts in astrocytoma’s 
contain clear yellow fluid, in contrast to the slightly turbid fluid in glioblastoma 
cysts. Diffuse astrocytoma’s insidiously invade brain tissue, but necrosis and 
microvascular proliferation are not features of the diffuse astrocytoma. 
 
 Cytologically, neoplastic cells in diffuse astrocytoma’s show mild atypia, 
particularly nuclear pleomorphism and hyperchromasia. The cells of previously 
called fibrillary astrocytoma’s may appear as bare nuclei, their tenuous fibrillary 
processes blending with the brain's parenchyma. Mitotic activity is not found in 
diffuse astrocytoma’s; it denotes anaplastic progression 90,91. 
 
ANAPLASTIC ASTROCYTOMA 
 Anaplastic transformation of an astrocytoma is often preceded by the 
development of rapidly worsening neurologic symptoms and signs. Focal increase 
in cell proliferation, nuclear pleomorphism is present and the nuclear: cytoplasmic 
ratio increased. Mitotic activity distinguishes the anaplastic astrocytoma. Necrosis 
is not found 92-94. 
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GLIOBLASTOMA- 
 Glioblastomas arise de novo or ultimately be the endpoint of neoplastic 
progression from an astrocytoma. Genetics of GB has been studied extensively, 
and based on the gene expression it has been classified into four types: 
 Classical, 
 Pro-neural, 
 Mesenchymal, 
 Neural. 
 
 Classical type is associated with chromosome 7 and 10 amplification and it 
occurs in younger individuals and is commonly associated with secondary GBM. 
The Proneural Type is associated with EGFR overexpression and alterations of 
PDGFRA it is responsive to therapy and is associated with primary GB. The 
Mesenchymal type is associated with NF mutation and deletions and offers a 
survival advantage and is associated with primary GB. About 90% of 
glioblastomas are primary or de novo. Grossly, GB is an infiltrating neoplasm. 
Glioblastomas appear as a spherical mass with a necrotic center, which is seen on 
MRI imaging as a ring of contrast-enhancing tissue around a region of low 
attenuation. The differential diagnosis will be an abscess, but the center of the 
glioblastoma is usually filled with straw-colored fluid and scanty necrotic debris. 
Sometimes, the tumor crosses the corpus callosum, sometimes forming a bi-
hemispheric mass called a ‘butterfly glioma’. Foci of cyst formation, necrosis, and 
hemorrhage. Microscopically, it resembles anaplastic astrocytoma, necrosis and a 
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florid microvascular proliferation are the key features distinguishing 
glioblastomas 95-108. 
 
GLIOMATOSIS CEREBRI- 
 Gliomatosis cerebri is characterized by disseminated infiltration of the 
CNS by small neoplastic glial cells. Typically, the cerebrum is involved, and this 
is sometimes accompanied by spread of neoplastic cells into the brain stem and 
even the spinal cord.  
The molecular genetics of this entity are poorly characterized. Gliomatosis cerebri 
can present like other neuroepithelial neoplasms, with headaches, focal 
neurological deficits, or epilepsy. Neuroimaging studies help us reach the 
diagnosis 109,110. 
 
MACROSCOPIC AND MICROSCOPIC APPEARANCES 
 Classic gliomatosis cerebri produces diffuse expansion of at least two 
cerebral lobes without an obvious tumor mass (type 1 gliomatosis cerebri). 
However, some produce the characteristic diffuse expansion of CNS tissue plus a 
mass of neoplastic cells (type 2 gliomatosis cerebri), which most often has the 
features of a glioblastoma. Generally, a moderate increase in cell density is seen 
in regions infiltrated by neoplastic cells. These cells have mildly pleomorphic 
nuclei and indistinct cytoplasm. Neoplastic cells tend to cluster around neurons 
and in subpial and perivascular spaces 109,110. 
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IMMUNOHISTOCHEMISTRY IN GLIOMA- 
 Immunohistochemistry(IHC) is of immense value in CNS neoplasms. IHC 
is a combination of immunology and histology and is based on the principle of 
localizing specific antigens in tissues or cells based on antigen-antibody 
recognition. It works on the principle of binding of an antibody with the 
corresponding antigen and its recognition therefore with the help of a chromogen. 
The different methods are Direct, Indirect and Polymer based methods. Out of 
these, Polymer based methods, by utilizing Horse Radish Peroxidase is commonly 
utilized as it has an increased sensitivity with minimal background staining and it 
also cuts short many of the steps involved with direct and indirect methods 111,112. 
 
 In CNS neoplasms, IHC plays a significant role in diagnosis and 
prognostication. Of great importance is the markers used for prognostication, 
which are –  
 
1. Cell cycle/proliferation markers-like KI 67, Proliferating Cell Nuclear 
Antigen(PCNA), Bromodeoxyuridine (BrDU) 
2. Tumor suppressor genes/oncogene protiens-p53 tumor suppressor gene, 
Retinoblastoma tumor suppressor gene, C-myc oncogene. 
3. Growth factors - Epidermal Growth Factor receptor 
4. Others - Isocitrate Dehydrogenase (IDH 1 and 2), ATRX (Alpha 
Thalassemia/mental retardation X linked) 111,112. 
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Ki 67 and MIB-1 
 Molecular immunology borstel-1 (MIB-1) antibody is an improvised 
version of Ki-67, which correlates with mitotic activity of the tumor. It recognizes 
an antigen expressed in all the active phases of cell cycle- G1, S, G2, and M in 
paraffin-embedded tissue. It helps in indicating the aggressiveness of the tumor. It 
is used as a prognostic marker, and correlates with the prognosis, including time 
to recurrence and survival and also correlates well with the histological grade of 
the tumor 113. 
 
P53 - 
 p53 is a tumor suppresser gene. It is coded by a tumor suppressor gene 
(p53 or TP53 gene) on chromosome 17p13.1. It is mainly responsible for the 
genomic stability of the cell. 
 
 It is considered as a marker of astrocytic tumor with a frequency that is in 
the range of 58–83%. Low-grade gliomas carrying this positivity are associated 
with a shorter survival and a shorter time interval to progress to high-grade 
gliomas. Secondary GB commonly show p53 mutations while primary GB. s 
rarely shows p53 mutations114,115. 
 
Iso-citrate dehydrogenase-1 and -2 
 Iso-citrate dehydrogenases (IDHs) are the enzymes that are involved in 
tricarboxylic acid cycle. They de-carboxylate isocitrate to α-ketoglutarate with the 
production of NADH and/or NADPH. In most of the IDH mutated genes, only 
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one copy of IDH gene is mutated. When IDH gene is mutated, there is a reduction 
of α-ketoglutarate to 2-hydroxyglutarate, which is increased in mutant gliomas 
and this has been implicated for the malignant progression of the tumor. 
IDH-1 mutation is present in 70-80% of WHO Grades II and III diffuse gliomas, 
ODGs (80%), anaplastic ODGs (85%), and mixed oligoastrocytomas (71%), as 
well secondary GBMs (82%). IDH-1 mutation is rare in primary GBMs (5%), 
pilocytic astrocytoma’s (10%), and is absent in ependymomas. IDH-2 mutation is 
seen in a smaller proportion of gliomas, and that too mainly in oligodendroglial 
tumors. IDH mutations have now been incorporated into the recent WHO 
classification. Several studies have shown that IDH-1 mutation is associated with 
a longer survival 113-116. 
 
ATRX  
 α-thalassemia/mental retardation syndrome X-linked (ATRX) protein is 
also seen in the nuclei of all normal cells. Mutation of ATRX gene leads to loss of 
its expression in tumor cells. ATRX mutation is considered as a specific marker 
for astrocytic lineage 117. 
 
EGFR AND MALIGNANCIES – 
 EGFR is a member of the ErbB family of tyrosine kinase receptors and 
they transmit a growth-inducing signal to cells that have been stimulated by an 
EGFR ligand (e.g., TGFα and EGF). In normal tissues, the EGFR ligands are 
tightly orchestrated to keep in check the kinetics of cell proliferation which 
maintains homeostasis.  
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 In malignancies, EGFR is often constitutively activated because of the 
sustained production of EGFR ligands in the tumor microenvironment Aberrant 
expression of EGFR by tumors typically confers a more aggressive phenotype and 
is thus predictive of poor prognosis. EGFR is a principal in targeted therapeutic 
intervention 118,119. 
 
Figure 1. EGFR protien and gene transcription.127 
 
Filip Janku, David J. Stewart & Razelle Kurzrock Nature Reviews Clinical 
Oncology 7, 401-414 (July 2010)-127 
 
EGFR AND GLIOMA - 
 The most frequent genetic alteration associated with Glioblastoma is 
amplification of the (EGFR) gene, which results in over expression of the EGFR. 
High protein levels of EGFR occur in about 90% of astrocytic tumors, suggesting 
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that alterations in transcription and translation of this gene may also participate in 
tumorigenesis 120-127. 
 
 Amplifications and rearrangements of EGFR are highly indicative of high-
grade gliomas. Expression of EGFR has been seen to significantly correlate with 
the histological grade of the glioma. Few studies show that EGFR immune-
positivity was significantly higher in grade III and IV gliomas compared with 
grades I and II 120-127. 
 
 EGFR as a marker serves for prognostication, Dysregulation of EGFR has 
also been shown to enhance tumor growth, migration, angiogenesis, and 
metastatic spread. Additionally, EGFR overexpression is a poor prognostic factor 
and correlates with decreased overall survival in GB patients 120-127. 
 
 Role of EGFR inhibitors aiming to promote apoptosis of cancer cells and 
increasing tumor sensitivity to possible adjuvant therapies is being extensively 
researched. 
 
 Recently, a study conducted by Fanny Burel et al, showed that EGFR 
expression in cell with high Nuclear Cytoplasmic ratio can enable differentiation 
between infiltrative gliomas and other non-infiltrative glial lesions (NIG), 
including gliosis, benign tumors, and demyelinating disease. This helps in 
distinguishing even low grade gliomas from other benign lesions, thereby 
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showing that EGFR is expressed in tumor cells of low grade glioma also, rather 
than only high grade gliomas of Grade 3 and 4 119-127. 
 
KI 67 AND MALIGNANCIES- 
 Ki-67 is a nuclear non-histone protein that is present at low levels in 
quiescent cells but is increased in proliferating cells, the expression of the Ki-67 
protein is strongly associated with cell proliferation. The fact that the Ki-67 
protein is present during all active phases of the cell cycle (G1, S, G2), but is 
absent from resting cells (G0) makes it an ideal marker for determining the 
fraction of cells undergoing active cell proliferation 123-125. 
 
KI 67 AND GLIOMA- 
 Various studies have shown that tumour grade in CNS neoplasms is the 
single most important factor in determining prognosis, it positively correlates with 
patient survival. Ki 67 is one of the most important prognostic markers that would 
help in classifying glioma. 
 
 Ki 67 expression is seen to increase positively with increasing grade of 
glioma. Higher the Ki 67 labelling index, higher is the grade which in turn related 
to bad prognosis and reduced survival of patients 123-125. 
  
Materials and Methods 
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MATERIALS AND METHODS 
 
 This study is both a retrospective and prospective descriptive 
clinicopathological analysis of gliomas in Department of Neuropathology, Rajiv 
Gandhi Government General Hospital, Chennai for a period of October 2015 to 
June 2017. 
 
SOURCES OF DATA: 
 Cases of glioma that were reported in the Department of Neuropathology, 
Rajiv Gandhi Government General Hospital and Madras Medical College, 
Chennai during a period of October 2015 to June 2017. 
 
INCLUSION CRITERIA- 
1. Patients diagnosed with gliomas-Ependymoma, Oligodendroglioma, 
Diffuse Astrocytoma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, 
Glioblastoma. 
2. According to WHO grading, tumors are either grouped as Grade I and II-
which are considered as low grade and Grade III and IV-considered as high 
grade 
 
EXCLUSION CRITERIA- 
 Non- neoplastic lesions of CNS, benign lesions of the CNS, Non- Glial 
tumors such as meningiomas, schwannomas etc. 
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METHOD OF DATA COLLECTION- 
 This is both a retrospective and prospective study where cases were 
between 2015 to 2017 were included. The relevant clinical details such as age, 
gender, symptoms, radiological findings, per operative squash findings, 
macroscopic and microscopic findings were retrieved from the Neuropathology 
registers between October 2015 to June 2017 and investigations were collected 
from medical records of Institute of Pathology, Madras Medical College, Chennai. 
Out of these, a total of 50 cases of Gliomas were randomly selected,25 cases of 
Low Grade Glioma and 25 cases of High Grade Glioma. There were Grade I (9 
cases), Grade II (16 cases), Grade III (4 cases), Grade IV (21 cases). 
 
 Corresponding paraffin blocks were collected, histopathological sections 
were prepared on a glass slide from formalin fixed paraffin embedded tissue of 
resected specimens. They were subjected to H and E staining and 
Immunohistochemical analysis by two markers EGFR and Ki 67. This was done 
for a total of 50 cases. The results were tabulated in a master chart and recorded 
with photographs. As much as possible, follow up data regarding adjuvant 
therapy, recurrence, disease free survival was obtained from Medical Records 
Section of Neurosurgery and oncology. 
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IMMUNOHISTOCHEMICAL EVALUATION- 
 IHC analysis was done using EGFR and Ki 67 in paraffin embedded tissue 
samples using poly excel detection system protocol.IHC was done for 50 cases.4-
micron thickness of paraffin embedded sections were taken and transferred to 
positively charged slides. Heat induced antigen retrieval was done using Tris 
EDTA buffer. The antigen is bound with rabbit monoclonal antibody (Pathinsitu) 
EGFR and Ki 67 followed by the addition of secondary antibody conjugated with 
horse radish peroxidase, this step is followed by addition of a chromogen 
Diaminobenzidine which imparts color. Hematoxylin is used as at the end as a 
counter stain. 
 
INTERPRETATION AND SCORING SYSTEM- 
 The immunohistochemically stained slides were analysed under the 
microscope for the presence or absence of reactivity as detected by the brown 
colour imparted by the brown product of Diaminobenzidine and various 
parameters were analysed namely- 
 
1. Cellular localization-for EGFR-membrane positivity and nuclear positivity 
for Ki 67 
2. Scoring for EGFR-For the marker, percentage of immunopositive cells was 
estimated by counting the number of positive cells in ten high power 
fields(40x), which were randomized throughout the section. For each field 
the ratio of positive cells/total number of cells was calculated in 
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percentage, then the mean value of ten fields was taken as estimated 
percentage of immunopositivity for that case and was allocated a value 
according to the following, 
 
a. 0-25%-Score 1 
b. 26%-50%-Score 2 
c. 51%-75%-Score 3 
d. 76%-100%-Score 4 
 
3. Ki 67-Nuclear positivity is looked for this marker and is scored as 
percentage of immunopositive cells per thousand cells 
 
  
Observation and Results 
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OBSERVATION AND RESULTS 
 
 We have received a total of 181 cases of various types of glioma in our 
institute of neuropathology from a period of October 2015 to June 2017.  
 
Table.1: Distribution of cases in the institute of neuropathology 
Diagnosis Number of cases Percentage 
Anaplastic astrocytoma 26 14.4 
Diffuse astrocytoma 46 25.5 
Clear cell ependymoma 1 0.5 
Myxopapillary ependymoma 1 0.5 
Ependymoma 11 6.1 
Oligodendroglioma 19 10.5 
Pilocytic astrocytoma 24 13.3 
Pilocytic astrocytoma with focal anaplasia 1 0.5 
Pleomorphic xanthoastrocytoma 1 0.5 
Glioblastoma 50 27.7 
Gliosarcoma 1 0.5 
Total 181 100 
 
 
 Among the 181 cases of glioma, the most commonly observed diagnosis 
was Glioblastoma, with a prevalence of 27.7%, followed by Diffuse Astrocytoma 
with a prevalence of 25.5%, Anaplastic Astrocytoma with a prevalence of 14.4%, 
Pilocytic Astrocytoma with 13.3% and Oligodendroglioma with 10.5%. Entities 
like Gliosarcoma, Myxopapillary Ependymoma, Clear cell ependymoma, 
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Pleomorphic Xanthoastrocytoma are rare, and were associated with lower 
prevalence rates. 
 
Figure 2. Distribution of Gliomas. 
 
 
AGE DISTRIBUTION- 
 Age distribution was tabulated individually for each glioma to highlight the 
correlation of each glioma pertaining to age of the patient. 
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PILOCYTIC ASTROCYTOMA: 
 These group of gliomas showed the maximum prevalence in the age group 
of 0-20 years amounting up to 66% of the cases. This age trend was found to be 
significant with a p value of 0.0002. 
 
Table 2. Distribution of Pilocytic Astrocytoma across various age groups. 
Age Group Number of cases Percentage 
0-10 9 37.5 
10-20 7 29 
20-30 4 17 
30-40 3 12.5 
40-50 0 0 
50-60 1 4 
60-70 0 0 
70-80 0 0 
Total 24 100 
 
Figure 3. Distribution of Pilocytic Astrocytoma across age groups. 
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OLIGODENDROGLIOMA- 
 About 32% of oligodendroglioma were seen to occur in the age group of 
30-40 years. 
 
Table 3. Age distribution of Oligodendrogliomas. 
Age Group Number of cases Percentage 
0-10 1 5.7 
10-20 3 15.8 
20-30 4 21.3 
30-40 6 31.6 
40-50 4 21.3 
50-60 1 5.3 
60-70 0 0 
70-80 0 0 
Total 19 100 
  p=0.0466 
 
Figure 4. Percentage Age Distribution of Oligodendrogliomas. 
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EPENDYMOMA- 
 Ependymoma was seen to occur most commonly in the age group between 
0 to 20 years, with 88% of cases occurring in this age group. This was found to be 
significant with a p value of 0.000088. 
 
Table 4. Age Distribution of Ependymoma. 
Age Group Number of Cases Percentage 
0-10 6 55 
10-20 3 27 
20-30 0 0 
30-40 2 18 
40-50 0 0 
50-60 0 0 
60-70 0 0 
70-80 0 0 
Total 11 100 
 
Figure 5. Age distribution of Ependymoma. 
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DIFFUSE ASTROCYTOMA- 
 Diffuse astrocytoma was distributed with majority of cases lying between 
the age group of 20 to 60 years, But the maximum percentage of patients (about 
30.4%) were seen in the age group of 30 to 40 years with a p value of 0.0002. 
 
Table 5. Age Distribution of Diffuse Astrocytoma. 
Age Group Number of Cases Percentage 
0-10 1 2.1 
10-20 4 8.7 
20-30 8 17.4 
30-40 14 30.4 
40-50 8 17.4 
50-60 9 19.6 
60-70 1 2.2 
70-80 1 2.2 
Total 46 100 
  p=0.0002 
 
Figure 6. Age Distribution of Diffuse Astrocytoma. 
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ANAPLASTIC ASTROCYTOMA 
 Anaplastic Astrocytoma cases showed an increasing distribution across the 
age groups and had maximum proportion (30.8%) of cases falling in the 51 to 60 
years age groups with a significant p value of 0.00081. 
 
Table 6. Age Distribution of Anaplastic astrocytoma. 
Age Group Number of Cases Percentage 
0-10 0 0 
11-20 1 3.8 
21-30 6 23.1 
31-40 4 15.4 
41-50 5 19.2 
51-60 8 30.8 
61-70 2 7.7 
71-80 0 0 
Total 26 100 
  p=0.00081 
 
Figure 7. Age Distribution of Anaplastic astrocytoma. 
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GLIOBLASTOMA- 
 Maximum proportion of cases of Glioblastoma were distributed between 
the ages of 40 to 70. The maximum percentage of cases were in the 40-50-year 
age group with a representation of 28% with a significant p value less than 
0.0001. 
 
Table 7. Age Distribution of Glioblastoma Multiforme. 
Age Group Number of Cases Percentage 
0-10 0 0 
10-20 1 2 
20-30 7 14 
30-40 3 6 
40-50 14 28 
50-60 13 26 
60-70 11 22 
70-80 1 2 
Total 50 100 
  p<0.0001 
 
Figure 8. Age Distribution of Glioblastoma Multiforme. 
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GENDER DISTRIBUTION 
 The gender distribution was studied for 181 cases and it was found that 
among the gliomas, Glioblastoma was significantly seen to occur in males with 32 
out of 50 cases occurring in males, with a significant p value of <0.047. 
 
Figure 9. Gender Distribution of Glioblastoma. 
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Table 9. Gender Distribution of Cases. 
Diagnosis Males Percentage Females Percentage 
Anaplastic Astrocytoma 15 57.7 11 42.3 
Clear Cell Ependymoma 1 100 0 0 
Diffuse Astrocytoma 27 58.7 19 41.3 
Ependymoma 7 63.6 4 36.4 
Glioblastoma(N=50) 32 64 18 36 
Gliosarcoma 1 100 0 0 
Myxopapillary Ependymoma 0 0 1 100 
Oligodendroglioma 12 63.2 7 36.8 
Pilocytic Astrocytoma 8 33.3 16 66.9 
Pilocytic Astrocytoma with Focal 
Anaplasia 1 100 0 0 
Pleomorphic Xanthoastrocytoma 1 100 0 0 
Total 105 58 76 42 
 
SITES AND SIDE OF GLIOMAS 
 The commonest site was Frontal with 24.3% of patients presenting here, 
while 11% and 9.9% of patients presented with glioma in the cerebellar and 
temporo-Parietal regions. 
 
 While observing the common side of occurrence of gliomas, it was seen 
that 45.3% of cases had gliomas on the left side and 29.3% of cases had it on the 
right side. Rest of the cases had a midline distribution. 
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Table 10. Distribution of Gliomas according to various sites in the Brain. 
Site Number of cases Percentage 
Fronto Temporal 8 4.4 
Thalamic 1 0.6 
Temporo Parietal 18 9.9 
4th ventricle 2 1.1 
Bifrontal 3 1.7 
Brainstem 2 1.1 
Corpus Callosal 10 5.5 
Cerebellar 20 11 
Cerebrum 1 0.6 
Cerebello Pontine Angle 1 0.6 
D12-L1 Intradural Intramedullary 1 0.6 
Dorsolumbar 1 0.6 
Fronto Parietal 14 7.7 
Frontal 44 24.3 
Intradural Extramedullary 1 0.6 
Insular 2 1.1 
Lateral Ventricle 1 0.6 
Middle Cranial Fossa 1 0.6 
Occipital 1 0.6 
Optic Chiasma 1 0.6 
Optic Nerve 1 0.6 
Para-sagittal 1 0.6 
Parasellar 1 0.6 
Parietal 13 7.3 
Parieto Occipital 9 4.9 
Posterior Fossa 6 3.3 
Supra-Sellar 1 0.6 
Temporal 10 5.6 
Temporo Occipital 1 0.6 
Thalamus 5 2.7 
TOTAL 181 100 
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Table 11. Distribution of Gliomas in different sides of the Brain. 
Side Number of cases Percentage 
Left 82 45.3 
Right 53 29.3 
Midline 46 25.4 
Total 181 100 
 
 When Observing Individual types of gliomas the presentation of site and 
sides changed accordingly. 
 
Anaplastic astrocytoma- 
 Showed a temporal lobe predilection in maximum number of cases (50%), 
while Parietal and Frontoparietal lobe presentation was seen in 15% cases each. 
 
Figure 10. Distribution of Anaplastic Astrocytoma according to site. 
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DIFFUSE ASTROCYTOMA 
 Showed maximum predilection for frontal region with 30%, followed by 
frontoparietal region with 19.6% 
 
Figure 11. Distribution of Diffuse Astrocytoma according to site 
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EPENDYMOMA 
 
 37% of cases were seen to afflict the posterior fossa followed by 18% of 
cases occurring in the fourth ventricle. 
 
 
Figure 12.Distribution of Ependymoma according to site 
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GLIOBLASTOMA- 
20 Percent of cases having Glioblastoma showed presentation of the 
disease, in Frontal and Temporo- Parietal areas. 10% of cases presented in Fronto-
Parietal and Parietal areas respectively. 
 
Figure 13. Distribution of Glioblastoma according to site 
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OLIGODENDROGLIOMA- 
 Maximum predilection was seen for the frontal lobe (48%), followed by 
temporo parietal region (16%). 
 
Figure 14. Distribution of oligodendroglioma according to site 
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PILOCYTIC ASTROCYTOMA- 
 Majority of the cases (67%), were seen to occur in the cerebellar region, 
the percentage of its occurrence in the other areas was 4% each. 
 
Figure 15. Distribution of Pilocytic Astrocytoma according to site 
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CORRELATION WITH HISTOLOGICAL PARAMETERS- 
 Histological parameters such as nuclear pleomorphism, vascular 
proliferation and mitosis were studied. 
 
NUCLEAR PLEOMORPHISM- 
 Nuclear pleomorphism was scored as Mild (1+), Moderate (2+). It was 
seen that 100% of Glioblastoma cases showed marked nuclear pleomorphism with 
a significant p value of <0.00078. It was also seen that 67.4% of Diffuse 
Astrocytoma exhibited mild nuclear pleomorphism. 100% of Ependymomas 
exhibited mild nuclear pleomorphism, whereas Oligodendroglioma and Pilocytic 
Astrocytoma showed mild nuclear pleomorphism in 94.7% and 95.8% of cases 
respectively. WHO Grade IV tumors were associated with marked nuclear 
pleomorphism. 
 
Table 12. Distribution of nuclear pleomorphism in glioma 
Diagnosis 
Nuclear Pleomorphism  
1+ Percentage 2+ Percentage P value 
Anaplastic Astrocytoma (n=26) 1 4% 25 96 0.00001 
Diffuse Astrocytoma (n=46) 31 67.4% 15 32.6% 0.0183 
Ependymoma (n=11) 11 100% 0 0% 0.0009 
Glioblastoma(n=50) 0 0% 50 100% 0.000078 
Oligodendroglioma(n=19) 18 94.7% 1 5.3% 0.000096 
Pilocytic astrocytoma (n=24) 23 95.8% 1 4.2% 0.000709 
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MITOSES- 
 Mitotic count was scored on the basis of presence (P) or absence (A) of 
mitosis. In Anaplastic Astrocytoma, 84.6% of cases show presence of mitosis, 
90% of Glioblastoma showed increased mitotic activity. The p value was found to 
be highly significant for Anaplastic Astrocytoma and Glioblastoma with p<0.01. 
Highly significant p values <0.01 was obtained for ependymoma, 
oligodendroglioma and diffuse astrocytoma, as 100% of the cases showed no 
mitoses. 
 
Table 13. Distribution of mitoses in glioma 
DIAGNOSIS 
Mitosis 
Present Percentage Absent Percentage 
Anaplastic astrocytoma 22 84.6 4 15.4 
Diffuse astrocytoma 0 0 46 100 
Ependymoma 0 0 11 100 
Glioblastoma 45 90 5 10 
Oligodendroglioma 0 0 19 100 
Pilocytic astrocytoma 0 0 24 100 
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Figure 16. Distribution of mitoses in glioma 
 
 
VASCULAR PROLIFERATION- 
Vascular proliferation observed in 181 cases was scored based upon its 
presence (P) or Absence (A). 86% of Glioblastoma showed vascular proliferation 
and this was found to be highly significant. None of the Diffuse Astrocytoma, 
Ependymoma, Oligodendroglioma and Pilocytic Astrocytoma showed vascular 
proliferation and this was found to be statistically significant (with p value <0.01). 
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Table 14. Distribution of vascular proliferation in glioma 
 
Figure 17. Distribution of vascular proliferation in glioblastoma 
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DIAGNOSIS 
Vascular Proliferation 
Present % Absent % 
Anaplastic Astrocytoma 16 61.5 10 38.5 
Diffuse Astrocytoma 0 0 46 100 
Ependymoma 0 0 11 100 
Glioblastoma 43 86 7 14 
Oligodendroglioma 0 0 19 100 
Pilocytic Astrocytoma 0 0 24 100 
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NECROSIS- 
 Necrosis was assessed based on its Presence (P), or Absence (A). Of all the 
181 cases studied, 92% of Glioblastoma showed necrosis. It was the only 
malignant glioma associated with necrosis, and this was statistically very 
significant with a p value <0.00025. 
Table 15. Distribution of necrosis in glioma 
Diagnosis 
Necrosis 
p value 
Present % Absent % 
Anaplastic Astrocytoma (n=26) 0 0 26 100 0.000314 
Diffuse Astrocytoma (n=46) 0 0 46 100 <0.0001 
Ependymoma (n=11) 0 0 11 100 <0.0001 
Glioblastoma (n=50) 46 92 4 8 0.000025 
Oligodendroglioma (n=19) 0 0 19 100 <0.0001 
Pilocytic Astrocytoma (n=24) 0 0 24 100 <0.0001 
 
Figure 18. Distribution of necrosis in glioblastoma 
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GRADING OF GLIOMAS- 
  Gliomas are graded according to WHO grading system, with Grade I and 
II correlating with Low grade gliomas and III and IV corresponding to high grade 
gliomas. In our Institute, 43.1% of the cases were Grade II tumors closely 
followed by Grade IV tumors with 28.2%. 
 
Table 16. Distribution of gliomas according to WHO Grade 
Grade Number of cases Percentage 
Grade I 25 13.8 
Grade II 78 43.1 
Grade III 27 14.9 
Grade IV 51 28.2 
Total 181 100 
 
CORRELATION OF AGE WITH GRADING- 
 The age of 181 patients was correlated with grading of glioma and it was 
found that 64% of patients with Grade I glioma were in the age group of 0-20 
years and this was found to be statistically significant with a p value of  .0077. 
43.7% of patients with Grade II glioma were in the age group of 20-40 years. This 
was not statistically significant. 
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 53% of patients with Grade III glioma were in the age group of 40-60 
years. This was statistically significant with p value <0.00778. 
 
 25.5% of patients with Grade IV glioma were in the age group of 60-80 
years. This was statistically significant with a p value of 0.0088 
 
Figure 19.Correlation of age with grading of gliomas 
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CORRELATION WITH HISTOLOGICAL PARAMETERS- 
 
Figure 20. Correlation of mitotic activity with grading of gliomas. 
 
 
 
 90.19% of patients having Grade IV glioma were found to be associated 
with mitoses and 81.48% of patients with Grade IV were found to be associated 
with mitoses. Both these were found to be highly significant with a p value of 
<0.01. 
  
0
0
81.48
90.19
0 20 40 60 80 100
I (n=25)
II (n=78)
III (n=27)
IV (n=51)
Percentage
G
ra
de
s
Comparison of Mitoses with Grading
 
64 
 
 
Figure 21. Correlation of vascular proliferation with grading of glioma 
 
 86.27% and 59.25% of patients with Grade IV and Grade III respectively, 
were seen to be associated with vascular proliferation and this was found to be 
highly significant with a p value of <0.01. 
 
Figure 22. Correlation between necrosis and Grading of Glioma 
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 In our study 92.15% of patients with Grade IV were found to have 
necrosis. Necrosis was not seen in any other grade and this was statistically very 
significant with a p value <0.001. 
 
IMMUNOHISTOCHEMICAL EXAMINATION OF GLIOMA-
CORRELATION WITH EGFR AND KI 67 EXPRESSION 
 The expression of EGFR and Ki 67 was studied in different types of 
glioma. A subset of 50 cases constituting 25 cases of low grade (WHO Grade I 
and II) and 25 cases of high grade (WHO grade III and IV) representative of the 
whole sample of 181 cases was chosen. The formalin fixed paraffin embedded 
sections of selected 50 cases was subjected to immunohistochemical analysis with 
EGFR and Ki 67. The list of cases are as follows. 
 
Table 17. List of cases for which immunohistochemical analysis was done 
Diagnosis Number of cases Percentage 
Anaplastic astrocytoma 4 8 
Diffuse astrocytoma 1 2 
Ependymoma 8 16 
Glioblastoma 21 42 
Oligodendroglioma 7 14 
Pilocytic astrocytoma 9 18 
Total 50 100 
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Figure 23.Distribution of cases for which immunohistchemical analysis was 
done 
 
 
  WHO grading of gliomas was done for all the 50 cases. Amongst these, 
42% of the cases were Grade IV,32% were Grade II,18% of cases were Grade I 
and 8% of cases were Grade III. 
 
Figure 24. Distribution of cases according to WHO grading system 
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DISTRIBUTION OF EGFR EXPRESSION IN GLIOMAS- 
 Out of 50 cases in total, 35 cases (70%) stained positive with EGFR. 
 
Table 18. Cases with expression of EGFR 
EGFR EXPRESSION NUMBER OF CASES PERCENT 
NEGATIVE 15 30 
POSITIVE 35 70 
 
Figure 25. Cases with expression of EGFR 
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DISTRIBUTION OF Ki 67 EXPRESSION IN GLIOMAS- 
 In the scoring done for Ki 67, the scoring was assigned based on 
percentage of immunopositive cells per thousand cells.26 out of 50 cases(52%) 
showed more than >5% positivity. 
 
Table 19. Cases showing expression of Ki 67 
KI 67 EXPRESSION NUMBER OF CASES PERCENT 
<5% 24 48.0 
>5% 26 52.0 
 
Figure 26. Cases showing expression of Ki67 
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Table 20. Correlation between expression of Ki67 and EGFR staining 
KI67_SCORE 
EGFR 
Total 
NEGATIVE POSITIVE 
<5% 
NEGATIVE 
Count 15 9 24 
% within EGFR 100.0% 25.7% 48.0% 
>5% POSITIVE 
Count 0 26 26 
% within EGFR 0.0% 74.3% 52.0% 
Total 
Count 15 35 50 
% within EGFR 100.0% 100.0% 100.0% 
Pearson Chi-Square=23.214** P<0.001 
 
 A total of 26 cases showed positivity (>5%) for Ki 67. All these 26 cases 
also showed positivity for EGFR (100%). 
 
 Of 35 cases that showed positivity for EGFR,74.3% of the cases also 
showed positivity for Ki 67 and 25.7% of cases were negative for Ki 67. 
 
 This was found to be significant with a p value <0.001. 
 
 Utilizing the above comparison between EGFR and Ki 67, a Sensitivity 
and Specificity analysis of EGFR was done. It showed a sensitivity of 74.29% 
(56.74-87.51%: -95% CI) and a Specificity of 100% (78.20%-100%). This 
showed a positive predictive value of 100%. 
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 Based on the above sensitivity and specificity results an ROC curve was 
plotted to visualize the results. The plot showed a straight line for Specificity, 
hence proving 100% Positive Predictive value 
Figure 27. ROC curve for sensitivity and Specificity. 
 
 
 
The area under the straight line was calculated as 0.917 with a standard 
error of 0.041 (0.838-0.997: -95% CI). 
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Table 21. Correlation between EGFR and WHO grading of gliomas 
EGFR 
WHO_GRADING 
Total 
I II III IV 
NEGATIVE 
Count 6 7 0 2 15 
% within 
WHO 
Grading 
66.7% 43.8% 0.0% 9.5% 30.0% 
POSITIVE 
Count 3 9 4 19 35 
% within 
WHO 
Grading 
33.3% 56.2% 100.0% 90.5% 70.0% 
Total 
Count 9 16 4 21 50 
% within 
WHO 
Grading 
100.0% 100.0% 100.0% 100.0% 100.0% 
 
Pearson Chi-Square=13.109** P=0.004 
 
 While comparing cases with EGFR positivity with WHO grading, it was 
observed that only 33.3% of Grade I patients, 56.2% of Grade II patients, 100% of 
Grade III patients, 90.5% of Grade IV showed positivity for EGFR. 
 
 These results show that Grade III and IV cases showed higher positivity for 
EGFR with a significant value of p=0.004. 
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Table 22. Correlation between Ki 67 and WHO grading of gliomas 
 
Pearson Chi-Square=11.728** P=0.008 
 
 On further examining correlation between Ki 67 and WHO grading, it was 
observed that 22.2% of Grade I patients, 31.2% of Grade II patients, 75% of 
Grade III and 76.2% of Grade IV patients showed increased mitotic activity of 
>5%. These results show that as and when compared to Grade I and II, Grade III 
and IV showed increased mitotic activity and staining for Ki 67. 
  
KI67_SCORE 
WHO_GRADING 
Total 
I II III IV 
<5% 
Count 7 11 1 5 24 
% within WHO 
Grading 77.8% 68.8% 25.0% 23.8% 48.0% 
>5% 
Count 2 5 3 16 26 
% within WHO 
Grading 22.2% 31.2% 75.0% 76.2% 52.0% 
Total 
Count 9 16 4 21 50 
% within WHO 
Grading 100.0% 100.0% 100.0% 100.0% 100.0% 
COLOUR PLATES 
 
 
Figure 1-100x view of Pilocytic Astrocytoma showing 
microcystic areas. 
 
 
 
Figure 2-400x view of Pilocytic Astrocytoma. 
 
 
  
  
 
Figure 3-100x view of Oligodendroglioma-with areas showing 
calcification. 
 
 
 
Figure 4-400 x view of Oligodendroglioma with halos seen around 
individual tumour cells-fried egg appearance. 
 
  
  
 
Figure 5-100x view of Ependymoma-perivascular pseudo rosettes seen 
 
 
 
Figure 6-400x view of Ependymoma 
 
  
  
Figure 7-100x view of Anaplastic Astrocytoma 
 
 
 
Figure 8-400x view of Anaplastic Astrocytoma 
 
  
  
Figure 9-100x view of Glioblastoma-with areas of extensive necrosis 
 
 
 
Figure 10-400x view of Glioblastoma 
 
  
  
Figure 11-IHC-EGFR showing strong membranous positivity in 
Glioblastoma 
 
 
 
Figure 12-IHC-Ki 67 labelling index->5% positivity in Glioblastoma 
 
  
  
Figure 13-IHC-EGFR showing strong membranous positivity in 
Anaplastic Astrocytoma 
 
 
 
Figure 14-IHC-Ki 67 labelling index in anaplastic astrocytoma 
 
  
  
Figure 15-IHC- EGFR showing weak staining in Pilocytic Astrocytoma 
 
 
 
Figure 16-IHC of Ki 67-showing <5% positivity in Pilocytic Astrocytoma 
 
  
  
Figure 17-IHC of EGFR showing weak staining in Oligodendroglioma 
 
 
 
Figure 18-IHC of Ki 67-showing <5% positivity in Oligodendroglioma 
 
Discussion 
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DISCUSSION 
 
 Gliomas are the most common primary brain tumors in adults.118. They are 
associated with a poorer survival outcome. 
 
 In the present study, histo-morphological study was done for 181 cases of 
glioma which were received in Rajiv Gandhi Government General Hospital, 
which is a tertiary referral center, while immunohistochemical evaluation was 
done for 50 cases. An attempt was made to check the correlation between EGFR, 
Ki 67 and gliomas. 
 
COMPARISON BETWEEN GENDER INCIDENCE OF GLIOMAS 
 In our study it was observed that the incidence of gliomas was increased in 
males, that is out of 181 cases, 105 cases (58%) were seen to occur in males, 
while 76 cases (42%) were seen to occur in females, this was seen to correlate 
with the study done by Vovorosa et al129. 
 
Table 23. Comparison between gender incidence of gliomas 
 CURRENT STUDY VOVOROSA ET AL 
MALE 58% 55.6% 
FEMALE 42% 45.4% 
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COMPARISON BETWEEN AGE INCIDENCE OF GLIOMAS- 
 In our study it was observed that the mean age of occurrence of gliomas 
was 37.7 years, this was in concurrence with the study conducted by X hu et al, 
where the mean age was 40.3 years. In this study 69% of the cases were within the 
age group 21-60 years, 21% of the cases were seen in <20 years of age, and the 
rest 10% were seen in the older age group. This was seen to concur with the study 
conducted by X Hu et al118. 
 
Table 24. Comparison between age incidence of gliomas 
Age Distribution X Hu et al Our Study 
<20 28% 21% 
21-60 55% 69% 
61-80 17% 10% 
.  
COMPARISON OF HISTOPATHOLOGICAL SUBTYPES OF GLIOMAS- 
 In our study conducted for a period of two years, the distribution of the 
cases were as follows, the most commonly observed diagnosis was Glioblastoma, 
with a prevalence of 27%, followed by Diffuse Astrocytoma with a prevalence of 
25.5%, Anaplastic Astrocytoma with a prevalence of 14.4%, Pilocytic 
Astrocytoma with 13.3% and Oligodendroglioma with 10.5%. Entities like 
Gliosarcoma, Myxopapillary Ependymoma, Clear cell ependymoma, Pleomorphic 
Xanthoastrocytoma are rare, and were associated with lower prevalence rates. 
These findings were in concordance with study of Larjavaara et al 130. 
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Table 25. Comparison between histopathological subtypes of gliomas 
Diagnosis Our study Larjavaara et al 
ANAPLASTIC ASTROCYTOMA 14.4% 9.4% 
EPENDYMOMA 6.1% 3% 
OLIGODENDROGLIOMA 10.5% 11% 
PILOCYTIC ASTROCYTOMA 13.3% 5% 
GLIOBLASTOMA 27.7% 47% 
DIFFUSE ASTROCYTOMA 25.5% 14% 
 
COMPARISON OF SIDE OF BRAIN INVOLVED IN GLIOMA- 
 In our study, the left hemisphere of brain was most commonly involved 
(45.3%), than the right side of the brain (29.3%). In the study conducted by 
Larjavaara et al, the right hemisphere was more commonly affected. This was 
probably because of variation in demographics of the mentioned study and our 
study 130. 
 
Table 26. Comparison between the side of brain involved in gliomas 
Side Our study Larjavaara et al 
Left 45.3% 41% 
Right 29.3% 50% 
Midline 25.4% 9% 
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COMPARISON OF THE SITE OF OCCURENCE OF GLIOMA- 
 In our study, out of 181 cases, it was found that 24.3% of the cases had a 
predilection for frontal lobe. This was similar to the study by Larjavaara et al 130. 
Temporal and parietal lobes are the next commonly affected lobes with 5.6% and 
7.3% respectively. Occipital lobe was the least commonly affected lobe with only 
0.6% of all the cases130. 
 
Table 27. Comparison between the site of occurrence of gliomas 
Site Our study Larjavaara et al 
Frontal 24.3% 40% 
Temporal 5.6% 29% 
Parietal 7.3% 14% 
occipital 0.6% 3% 
Cerebellum 11% 1.5% 
Ventricle 1.7% 2.2% 
Brainstem 1.1 4.1% 
 
COMPARISON OF WHO GRADING OF GLIOMAS- 
 In our study, it was observed that WHO grade II tumors were of maximum 
incidence (43.1%), the second most common was Grade IV tumors with (28.2%), 
the third most common was Grade III with (14.9%), the fourth most common was 
Grade I tumors with (13.8%). In the study conducted by Larjavaara et al, Grade 
IV tumors showed the maximum incidence with 46.5%. The incidence of grade III 
and IV tumors was similar to our study 130. 
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Table 28. Comparison between WHO grading of gliomas 
 
ANALYSIS OF IMMUNOHISTOCHEMICAL PARAMETERS 
 The expression of EGFR and Ki 67 was studied in different types of 
glioma. A subset of 50 cases constituting 25 cases of low grade (WHO Grade I 
and II) and 25 cases of high grade (WHO grade III and IV) representative of 
whole sample of 181 cases. The formalin fixed paraffin embedded sections of 
selected 50 cases was subjected to immunohistochemical analysis with EGFR and 
Ki 67. 
 
 In our study, the expression of Ki 67 was also seen to increase with 
increasing grades of glioma. In the scoring done for Ki 67, the scoring was 
assigned based on percentage of immunopositive cells per thousand cells. 26 out 
of 50 cases (52%) showed more than >5% positivity, with a significant p value of 
p=0.008. 
 
 The median value of Ki 67 positivity was 2 in Grade I, 2 in Grade II, 7.75 
in Grade III and 23.5 in Grade IV in our study. On comparing the cumulative 
median values, it was observed that Grade III and IV showed higher Ki 67 
Grade Our study Larjavaara et al 
Grade I 13.8% 5.13% 
Grade II 43.1% 38.9% 
Grade III 14.9% 9.36% 
Grade IV 28.2% 46.5% 
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positivity with a p value of 0.00011. This was in concordance with the study 
conducted by Skjulsvik AJ et al 131. 
 
Table 29. Comparison between Ki 67 expression 
  
COMPARISON OF EGFR POSITIVITY- 
 Among the 50 cases, EGFR expression was seen in 35 cases (70%), p 
value was found to be significant with (p=0.004) The expression was seen to be 
higher in high grade gliomas than in low grade gliomas and this was in correlation 
with the study conducted by X Hu et al and Richard Montogomery et al 118,132. 
  
Grade 
Our Study Skjulsvik AJ et al 
Number 
of cases 
Median 
Ki67 
value 
Range Number of cases 
Average 
Median 
Ki67 
value 
Range 
I 9 2 2-47 21 1.45 0.7-8.5 
II 16 2 2-20.2 110 3.9 0.5 -25.3 
III 4 7.75 3-22.7 47 15.83 2.1-41.2 
IV 21 23.5 2-74 89 19.4 2.2-80 
Total 50   267   
p=0.00011    p<0.001   
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Table 30. Comparison between expression of EGFR 
 
 EGFR grading was done and the scoring was done based on percentage of 
immunopositive cells 
 0-25% - Score 1 
 26%-50% - Score 2 
 51%-75% - Score 3 
 76%-100% - Score 4 
 
 In our study, it was observed that EGFR staining increased with increasing 
grades of gliomas. In grade I gliomas it was seen that out of 9 cases, 6 cases 
(66.67%) were negative for EGFR staining, 2 cases (22.2%) showed Score 2. In 
Grade II, out of 16 cases, 7 cases (43.75%) were negative for EGFR and 5 cases 
(31.25%) showed score 1, 1 case (6.25%) showed score 2 and 3 cases 
(18.75%)showed score 4. In Grade III, out of 4 cases all showed positivity for 
EGFR, with all the cases showing strong positivity for EGFR with Score 4. In 
Grade IV, out of 21 cases, 2 cases (9.52%) showed Score 1, 3 cases (14.29%) 
showed score 3, and 12 cases (57.5%) showed strong positivity with score 4. The 
Grade Our study X Hu et al 
Grade I 33.3% 22.2% 
Grade II 56.2% 44.6% 
Grade III 100% 71.2% 
Grade IV 90.5% 88.6% 
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above findings were in concurrence with the study of both X Hu et al and Richard 
Montogomery et al 118,132. 
 
Table 31. Correlation between EGFR expression and WHO Grading of 
gliomas in our study 
EGFR Result 
Grade Negative n (%) 
Positive, n (%) 
Total 
Positive,  
n (%) 
Total 
Cases,  
N 
EGFR Score 
1+ 2+ 3+ 4+ 
I 6 (66.67) 0 (0) 2 (22.22) 0 (0) 1 (11.11) 3 (33.33) 9 
II 7 (43.75) 5 (31.25) 1 (6.25) 0 (0) 3 (18.75) 9 (56.25) 16 
III 0 (0) 0 (0) 0 (0) 0 (0) 4 (100) 4 (100) 4 
IV 2 (9.52) 2 (9.52) 2 (9.52) 3 (14.29) 12 (57.15) 19 (90.48) 21 
 
Table 32.Comparison between EGFR expression and  
WHO grading-study by x hu et al 
GRADE IMMUNO NEGATIVE CASES 
IMMUNOPOSITIVE CASES 
TOTAL 
+ ++ +++ 
I 7 (77.8%) 2 (22.2%) 0 0 2 (22.2%) 
II 3 (55.4%) 15 (26.8%) 6 (10.7%) 4 (7.1%) 
25 
(44.6%) 
III 15 (28.8%) 8 (15.4%) 17 (32.7%) 
12 
(23.1%) 
37 
(71.2%) 
IV 4 (11.4%) 3 (8.6%) 10 (28.6%) 
18 
(51.4%) 
31 
(88.6%) 
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Table 33. Comparison between EGFR and Ki 67 positivity in our study 
KI67_SCORE 
EGFR 
Total 
NEGATIVE POSITIVE 
<5% NEGATIVE 
Count 15 9 24 
% within EGFR 100.0% 25.7% 48.0% 
>5% POSITIVE 
Count 0 26 26 
% within EGFR 0.0% 74.3% 52.0% 
Total 
Count 15 35 50 
% within EGFR 100.0% 100.0% 100.0% 
Pearson Chi-Square=23.214** P<0.001 
 
 In our study, a comparison and correlation between EGFR and Ki 67 was 
done, a total of 26 cases showed >5% positivity for Ki 67. All these 26 cases also 
showed positivity for EGFR (100%). 
 
 Of 35 cases that showed positivity for EGFR, 74.3% of the cases also 
showed positivity for Ki 67 and 25.7% of cases were negative for Ki 67. 
 
 This was found to be significant with a p value <0.001. 
 
 This correlation between EGFR and Ki 67 showed that in Grades III and 
IV, the expression of EGFR was strong and also associated with increase in the Ki 
67 index, reflecting the mitotic activity of these higher-grade tumors. This 
correlation between these two markers was highly significant with a p value 
of<0.001. 
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 Furthermore, a Sensitivity and Specificity analysis of EGFR was done. It 
showed a sensitivity of 74.29%(56.74-87.51%: -95% CI) and a Specificity of 
100% (78.20%-100%).This showed a positive predictive value of 100%. 
 
  
Summary 
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SUMMARY 
 In the current study,181 cases were analysed histomorphologically while 
immunohistochemical evaluation was done for a subset of 50 cases with two 
markers, EGFR and Ki 67 respectively. 
 The mean age of occurrence of gliomas was found to be 37.7 years, with peak 
incidence occurring in the age group of 21-60 years, while least incidence was 
seen in >80 years of age. 
 There was seen to be a male preponderance with 58% of cases occurring in 
males as and when compared to females. 
 Amongst the gliomas in our institute, the maximum number of cases were 
observed to be glioblastoma with 27.7%, followed by diffuse astrocytomas 
with 25%, the least commonly diagnosed gliomas were Ependymomas. 
 The site of predilection for gliomas was found to be the Frontal lobe with 
24.3% of cases occurring in this region, the occipital lobe showed the least 
occurrence of cases. 
 The side of predilection was observed to be the left side with 45.3% of cases 
occurring on the left side. 
 Maximum number of cases were falling under the category of WHO grade II, 
(43.1%) of cases, followed by WHO Grade IV, (28.1%) 
 Immunohistochemical evaluation was done for a subset of 50 cases with 
EGFR and Ki 67. For EGFR,35 out of 50 cases (70%) showed positivity and it 
was also observed that the positivity increased with increasing grades of 
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glioma with the maximum positivity seen in Grades III and IV tumors. This 
association was found to be statistically significant. 
 For Ki 67, 26 out of 50(52%) cases showed >5% labelling index and it was 
also observed that the labelling index increased as the grade of the tumor 
increased. 
 This correlation between EGFR and Ki 67 showed that in Grades III and IV, 
the expression of EGFR was strong and also associated with increase in the Ki 
67 index, reflecting the mitotic activity of these higher-grade tumors. This 
correlation between these two markers was highly significant with a p value 
of<0.001. 
 Sensitivity and Specificity analysis of EGFR was done. It showed a sensitivity 
of 74.29%(56.74-87.51%: -95% CI) and a Specificity of 100%(78.20%-
100%).This showed a positive predictive value of 100%. 
  
Strengths of the study 
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STRENGTHS OF THE STUDY 
 
 The study spans for a period of 2 years, done at a tertiary care hospital in 
Southern India 
 The clinicopathological aspects of glioma-their incidence, age distribution, 
gender predilection, site of involvement has been studied extensively, 
which can add value to any future population based studies. 
 There was seen to be a strong association of EGFR and Ki 67 with high 
grade gliomas, Grade III and IV in our study. 
 Sensitivity and specificity analysis of EGFR was done, and it was found to 
be statistically significant. 
 This study helps determine the quality of EGFR as a prognostic marker in 
glioma and is also useful in evaluation of prospective targeted therapy. 
 
  
Limitations of the study 
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LIMITATIONS OF THE STUDY 
 
 Study is hospital based, it does not reflect the true incidence and prevalence 
in the community. 
 Few cases were lost to follow up. 
 Immunohistochemical analysis could not be done for all cases due to 
economic restraints. 
 
  
Conclusion 
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CONCLUSION 
 
 Th incidence of gliomas is on the rise and it is seen that the prognosis 
depends on numerous factors like age, site of occurrence. In our study it is seen 
that EGFR and Ki 67 expression increases with increasing grades of glioma. Thus, 
proving that these markers can be used to predict the behavior of these tumors and 
thereby the prognosis. 
 
 In this era of targeted therapy, EGFR inhibitors are being extensively 
researched upon and this study opens up realms on targeted therapy in high grade 
gliomas. 
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MASTER CHART – Statistics of Gliomas for the period of 2 years from Oct 2015 to Jun 2017 
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1 006/17 25 F R F 3 2+ P P P GBM IV P  77 4 3 
2 008/17 14 M 
 
BS 3 1+ A A A 
 
ODG II P  10 1 <2 
3 010/17 44 F 
 
IDEM 3 1+ A A A 
 
PA I 
    4 017/17 19 M R F 3 1+ A A A GBM IV 
5 100/16 65 M L F 3 2+ P A P AA III 
6 101/17 65 M R FP 3 2+ P A A 
 
GBM IV P  87.5 4 10.5 
7 104/16 12 M Ce 3 1+ A A A P ODG II N  0 1 <2 
8 105/16 30 F L TP 3 1+ A A A P DA II 
9 106/17 46 M L FTP 3 2+ P A A DA II 
10 109/16 30 M 
 
CC 3 1+ A A A 
 
ODG II 
    11 110/16 45 F L P 3 2+ P A A DA II 
12 112/16 35 F L FT 3 2+ P A P DA II 
13 116/17 60 M L PO 3 2+ P A A 
 
DA II P  88.7 4 22.7 
14 119/16 59 M R F 3 1+ A A A P GBM IV 
    15 124/16 14 M Ce 3 1+ A A A ODG II N  0 1 <2 
16 126/16 52 M CC 3 1+ A A A ODG II 
17 126/17 15 M 
 
Ce 3 1+ A A A P PA I P  60 1 20.2 
18 130/16 12 F Ce 3 1+ A A A P ODG II N  0 1 <2 
19 131/17 30 M R F 3 2+ P P P  GBM IV P 71 3 63.75 
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20 138/17 18 M L P 3 2+ P A A  DA II P 79.5 4 5 
21 139/17 55 M L PO 3 2+ P P P   DA II P  86 4 39 
22 141/17 48 M L TP 3 2+ P P P  DA II P 79.5 4 3 
23 144/16 35 F L Ce 3 1+ A A A  AA III P 24 2 8 
24 149/16 42 M L P 3 1+ A A A  DA II     
25 150/17 29 M L PO 3 1+ A A A  DA II     
26 154/16 22 F  Ce 3 1+ A A A  PA I     
27 156/16 32 M L F 3 1+ A A A  AA III     
28 157/16 36 F R F 3 1+ A A A  GBM IV     
29 157/17 32 F L FP 3 1+ A A A  AA III     
30 159/17 50 M  Su Se 3 2+ P P P  PAFA II P 73 3 7 
31 167/16 60 F L FP 3 1+ A A A  AA III     
32 169/17 67 M R TP 3 2+ P P P  GBM IV     
33 170/16 46 M  F 3 1+ A A A  ODG II     
34 172/16 43 M L F 3 1+ A A A A DA II     
35 176/15 24 F L FP 3 2+ P P A  AA III     
36 177/15 60 M L TP 3 1+ A A A  EPEN II     
37 179/17 53 F L PO 3 1+ A A A  DA II     
38 180/15 29 F R P 3 2+ P P P  GBM IV     
39 183/17 48 M L FTP 3 2+ P P P  AA III P 81.5 4 73.5 
40 185/15 51 F R F 3 2+ A A A  GBM IV     
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41 187/17 48 M R TP 3 2+ P P P   GBM IV         
42 199/15 45 F L Th 3 1+ A A A   AA III         
43 199/16 60 F   CC 3 1+ A A A   ODG II         
44 200/16 2 F   IV 3 1+ A A A   ODG II P  86 4 <2 
45 201/15 17 F   IDEM 3 2+ A A A   PA I         
46 203/17 18 M L TP 3 2+ P P P   DA II         
47 205/15 48 M L Th 3 2+ P P P   DA II         
48 212/15 33 F   DL 3 2+ P P A   PA I         
49 215/16 10 F R BS 3 1+ A A A   GBM IV         
50 219/16 65 M R T 3 1+  A A A   GBM IV         
51 221/15 25 M L F 3 2+ P P A   DA II         
52 221/16 47 M L F 3 2+ P A A   AA III P  88 4 74 
53 222/15 45 F R Th 3 2+ A A A   GS IV         
54 228/15 57 M   CC 3 2+ P P P   PA I         
55 229/16 54 F R T 3 1+ P P A   GBM IV         
56 230/17 12 M   Po Fo 3 1+ A A A   PA I P  13.77 1 <2 
57 231/15 27 F   CC 3 2+ P P P   PA I         
58 233/15 34 M R FP 3 2+ A A A   GBM IV         
59 235/16 13 M   Po Fo 3 1+ A A A   PA I P  26 2 17.4 
60 243/16 22 M L PO  3 2+ A P P   DA II P  86 4 49 
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61 245/15 35 M L F 3 2+ A A A  EPEN   II     
62 245/16 58 F L P 3 2+ P P P  EPEN   II     
63 25/17 35 F L F 3 1+ A A A  AA III     
64 250/16 14 M  Po Fo 3 1+ A A A  PA I P  88 4 15 
65 258/16 16 M  T 3 1+ A A A  PA I     
66 266/16 55 M R F 3 2+ A A A  GBM IV     
67 269/15 30 M L F 3 2+ A A A  EPEN   II     
68 278/16 48 M  F 3 2+ A P P  ODG II     
69 279/15 40 M L P 3 2+ P P A  DA II     
70 28/17 57 F L T 3 2+ P P A  DA II     
71 281/16 40 M R F 3 A A A A  GBM IV     
72 287/16 70 M L FT 3 2+ P P P  DA II     
73 288/16 35 F R On 3 1+ A A A  GBM IV     
74 290/16 53 F L F 3 2+ P P P  CCEP III P  93.5 4 61.5 
75 295/15 25 F L TP 3 2+ A A A  EPEN   II     
76 303/16 24 F  Ce 3 1+ A A A  PA I     
77 304/16 61 M L TP 3 2+ P P P  DA II     
78 318/16 39 M L FP 3 1+ A A A  AA III     
79 327/16 28 M R TP 3 2+ P P P  GBM IV     
80 334/16 8 M L Ce 3 1+ A A A  AA III     
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81 336/16 42 M L F 3 2+ P P P   EPEN   II         
82 339/15 60 M L P 3 2+ P P P   EPEN   II         
83 348/16 30 F R F 3 1+ A A A   GBM IV         
84 35/17 55 F R T 3 2+ P P A   GBM IV         
85 352/16 6 M L Th 3 1+ A A A   DA II         
86 362/16 19 F L T 3 1+ A A A   DA II N  0 1 <2 
87 364/15 21 F R FTP 3 2+ A A A   GBM IV         
88 366/16 2 F R On 3 1+ A A A   GBM IV         
89 369/15 27 M R PO 3 2+ P P A   GBM IV         
90 380/16 30 M R F 3 1+ A A A   GBM IV         
91 381/15 65 M L FP 3 2+ P P P   DA II         
92 383/16 8 M L FP 3 1+ A A A   AA III         
93 385/16 40 F L F 3 1+ A A A   DA II         
94 387/15 40 M   FTP 3 2+ A A A   PA I         
95 388/15 46 M   CC 3 2+ A A A   PA I         
96 393/15 30 F   F 3 2+ P P P   ODG II         
97 4 0 5 34 M   IV 3 1+ A A A   ODG II         
98 402/16 14 M   Ce 3 1+ A A A A PA I         
99 407/15 75 M   CC 3 2+ A A A   PA I         
100 408/15 60 F L F 3 2+ P P P   EPEN   II         
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101 41/17 51 M   Th 3 2+ P P P   PXA II P  48 2 5 
102 417/15 25 F R TP 3 2+ P P A   EPEN   II         
103 430/16 33 F L PaSe 3 1+ A A A   DA II         
104 432/16 55 F L FT 3 2+ P P P   DA II P  76.3 4 54.7 
105 434/16 62 M   CC 3 2+ P P P   ODG II N  0 1 <2 
106 435/15 33 M R FP 3 2+ A A A   GBM IV         
107 435/16 17 F   Ce 3 1+ A A A   PA I         
108 437/15 40 F R PO  3 1+ A A A   GBM IV         
109 438/15 25 M L F 3 2+ P P A   DA II         
110 444/16 15 F R F 3 1+ A A A   GBM IV         
111 450/15 67 F R FP 3 1+ A A A   GBM IV         
112 46/17 60 M R T 3 1+ A A A   GBM IV         
113 465/15 30 M L T 3 2+ A A A   DA II         
114 466/16 52 F L P 3 1+ A A A   DA II         
115 469/15 27 F R P 3 2+ P P A   GBM IV         
116 471/15 60 M L Th 3 2+ A A A   DA II         
117 477/15 40 M R TP 3 2+ P P P   ODG II         
118 477/16 31 M L F 3 1+ A A A P DA II N  0 1 <2 
119 48/17 40 M R F 3 1+ A A A   GBM IV         
120 488/16 45 M R FP 3 2+ P P P   GBM IV P  83 4 7.4 
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121 491/15 50 F R TP 3 2+ A A A   MPEP I         
122 494/16 38 M L FTP 3 2+ A A A   DA II P  20 1 <2 
123 497/16 40 M L T 3 1+ A A A   DA II         
124 506/15 56 M R F 3 2+ P P A   GBM IV         
125 507/15 40 M L TP 3 2+ P P A   AA III         
126 507/16 23 M L F 3 1+ A A A   AA III         
127 513/16 12 M R F 3 1+ A A A   GBM IV         
128 523/16 33 M L TP 3 1+ A A A   EPEN   II         
129 527/15 62 M L FTP 3 2+ P P P   AA III         
130 528/16 52 M L T 3 2+ P P A   EPEN   II P  89.7 4 32 
131 53/17 13 F   BS 3 1+ A A A   ODG II P  47 2 <2 
132 534/16 50 F L TP 3 2+ P P P   DA II         
133 535/16 67 M L F 3 2+ A P A   AA III         
134 538/16 32 M L F 3 1+ A A A   AA III         
135 539/16 47 F R F 3 2+ A P A   GBM IV         
136 547/16 60 F L F 3 2+ P P P   DA II P  95% 4 49.5 
137 548/16 61 F R P 3 2+ P P P   GBM IV         
138 55/17 58 F L P 3 1+ A A A   DA II         
139 56/17 38 M R F 3 2+ A P A   GBM IV         
140 560/16 25 F   Po Fo 3 1+ A A A   PA I P  24 1 6.5 
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141 565/16 7 F   Ce 3 1+ A A A   PA I         
142 568/16 37 M L F 3 1+ A A A   AA III         
143 569/16 45 M L F 3 2+ P P P   DA II P  17.8 1 <2 
144 579/16 50 F L F 3 1+ A A A   AA III         
145 58/17 60 F R T 3 2+ P P P   GBM IV         
146 590/17 13 F L F 3 1+ A A A   AA III         
147 597/16 13 M R Ce 3 1+ A A A   GBM IV         
148 598/16 17 M R TP 3 1+ A A A P GBM IV N  0 1 <2 
149 60/17 58 M R F 3 2+ P A A   GBM IV         
150 601/16 47 F L FP 3 2+ P A A   AA III         
151 612/16 35 M L PO 3 2+ P P P   DA II P  85 4 23.5 
152 614/16 40 F L P 3 1+ A A A   DA II         
153 616/16 14 F L Ce 3 1+ A A A P AA III N  0 1 <2 
154 619/16 66 F L FP 3 2+ P P P   AA III P  58.5 3 16.3 
155 625/16 37 F   Po Fo 3 1+ AA A A   PA I N  0 1 <2 
156 630/16 7 M L F 3 1+ A A A   DA II N  0 1 <2 
157 631/16 47 F R F 3 1+ A A A   GBM IV         
158 633/16 15 F   Ce 3 1+ A A A   PA I N  0 1 <2 
159 636/16 2 M R Ce 3 1+ A A A   GBM IV N  0 1 <2 
160 645/16 9 M   Ce 3 2+ A A A   PA I         
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161 650/16 10 M   Po Fo 3 1+ A A A   PA I         
162 66/17 16 F   IV 3 1+ A A A   PA I N  0 1 <2 
163 70/16 45 M R O 3 2+ P A A   GBM IV         
164 71/16 42 F L TP 3 2+ A A A   DA II         
165 72/16 65 M R TP 3 2+ P P P   GBM IV         
166 73/16 28 F   Ce 3 1+ A A A   ODG II P  95.1 4 47 
167 74/17 52 M R F 3 2+ P A A   GBM IV         
168 75/17 50 F R F 3 2+ P A A   GBM IV         
169 76/17 27 M L F 3 1+ A A A   DA II P  75 4 5.3 
170 77/17 65 M R F 3 2+ P P P   GBM IV P  89 4 43 
171 80/17 45 M   CC 3 1+ A A A   ODG II         
172 82/16 55 F L TP 3 2+ A A P   DA II         
173 87/16 50 M L FT 3 1+ A A A   DA II         
174 87/17 60 M R PO 3 2+ P P P   GBM IV P  10 1 <2 
175 90/16 12 F   Ce 3 1+ A A A   ODG II N  0 1 <2 
176 92/16 43 F   CC 3 2+ P P P   ODG II         
177 93/16 62 M L P 3 2+ A A P   DA II         
178 94/17 47 F L CC 3 1+ A A A   DA II         
179 96/16 27 M L Ce 3 2+ A A A   AA III         
180 97/17 7 M L Ce 3 1+ A A A   AA III         
181 98/17 72 F R FP 3 2+ P P P   GBM IV P  27 2 5 
KEY TO THE MASTER CHART 
 Age-in years 
 Sex-M-male, F-female 
 Side-Right-R,left-L 
 Site - 
F Frontal 
FP Frontoparietal 
FT Frontotemporal 
FTP Frontotemporoparietal 
T Temporal  
TP Temporoparietal  
P Parietal 
O Occipital 
PO Parieto occipital 
CC  Corpus callosum 
On Optic nerve sol 
IDEM Intradural extramedullary 
IV Intraventricular  
Po Fo Posterior fossa  
Th Thalamus 
Ce Cerebellum  
BS Brainstem 
Pa Se Parasellar 
 
  
CELLULARITY- 
1-LOW 
2-MODERATE 
3-HIGH 
 
NP-NUCLEAR PLEOMORPHISM 
1+-MILD NUCLEAR PLEOMORPHISM 
2+-MARKED NUCLEAR PLEOMORPHISM 
 
MITOSES- 
A-ABSENT 
P-PRESENT 
 
VASCULAR PROLIFERATION-VP 
A-ABSENT 
P-PRESENT 
 
NECROSIS-NEC 
A-ABSENT 
P-PRESENT 
CALCIFICATION-CA 
A-ABSENT 
P-PRESENT 
 
MICROSCOPIC DIAGNOSIS- 
PA-Pilocytic Astrocytoma 
PA with FA-Pilocytic Astrocytoma with focal anaplasia 
EPEN-Ependymoma 
CCEP-Clear cell ependymoma 
MPEP-Myxopapillary Ependymoma 
  
 DA-Diffuse Astrocytoma 
PXA-Pleomorphic Astrocytoma 
ODG-Oligodendroglioma 
AA-Anaplastic Astrocytoma 
GBM-Glioblastoma multiforme 
GS-Gliosarcoma 
 
IHC- 
EGFR-POS-positive 
            NEG-negative 
EGFR Scoring-Percentage of stained cells 
1-0-25% 
2-26%-50% 
3-51%-75% 
4-76%-100% 132 
